+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Febrile Neutropenia Drug Pipeline Analysis Report 2025

  • PDF Icon

    Drug Pipelines

  • 200 Pages
  • June 2025
  • Region: Global
  • Expert Market Research
  • ID: 6102797
According to the JAMA Journal, neutropenic fever occurs in approximately 30% of cancer patients receiving chemotherapy. It affects more than 60,000 patients annually in the United States. In several studies, the mortality rate of febrile neutropenia is reported from 5.4% to 15%. First-line treatment options for febrile neutropenia include fluoroquinolone monotherapy such as moxifloxacin or ciprofloxacin in combination with amoxicillin/clavulanic acid. The condition is a frequent event in cancer patients taking chemotherapy, several clinical trials are addressing the efficacy of colony-stimulating factors for the prevention and treatment of febrile neutropenia.

Report Coverage

The Febrile Neutropenia Drug Pipeline Insight Report by the publisher gives comprehensive insights into febrile neutropenia clinical trials. It covers various aspects related to the details of each of these drugs under development for febrile neutropenia. The report includes the analysis of over 100 pipeline drugs and 50+ companies . The febrile neutropenia pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from febrile neutropenia.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing febrile neutropenia product development activities related to febrile neutropenia.

Febrile Neutropenia Drug Pipeline Outlook

Neutropenia is characterized by lower than normal levels of neutrophils in the blood. Febrile neutropenia is the occurrence of fever during a period of neutropenia. A neutrophil is a white blood cell type which bone marrow primarily makes. It destroys germs which cause infections such as viruses and bacteria. When a patient suffers from neutropenia, their risk of getting an infection is higher than normal. Infections can be transmitted from infectious agents between people or sometimes because of organisms which live in the gut, mouth, or on the skin.

The diagnosis of febrile neutropenia includes blood tests, x-rays, or urine samples. Cancer treatments such as chemotherapy destroy cancer cells along with healthy neutrophils and the bone marrow which makes healthy white blood cells.

The treatment for this condition includes corticosteroids, antibiotics, and granulocyte colony-stimulating factors among others. Antibiotics are the major treatment for febrile neutropenia, administered intravenously to fight the infection. Corticosteroids are prescribed in case of autoimmune conditions. These drugs help in suppressing the body’s immune response which is causing the destruction of neutrophils. Granulocyte colony-stimulating factors are prescribed to promote the production of white blood cells in bone marrow. Several pharma companies and research institutes are developing innovative treatments to manage the condition. Clinical trials are focused on addressing the efficacy of colony-stimulating factors in the prevention and treatment of febrile neutropenia. The increasing clinical trials and changing dynamics are impacting the febrile neutropenia clinical trial landscape significantly.

Febrile Neutropenia - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of Febrile Neutropenia drug candidates based on several segmentations including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

By Drug Class

The Febrile Neutropenia therapeutic assessment report covers 50+ drug analyses based on drug classes:

  • Peptides
  • Recombinant Proteins
  • Small Molecule

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration:

  • Oral
  • Parenteral
  • Others

Febrile Neutropenia - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III covers a major share of the total clinical trials for febrile neutropenia.

Febrile Neutropenia - Pipeline Assessment Segmentation, By Drug Classes

The drug molecules categories covered under febrile neutropenia pipeline analysis include peptides, recombinant proteins, and small molecules. In a study conducted, Filgrastim significantly reduced the incidence and duration of infection of febrile neutropenia. Filgrastim is a biologic drug specifically a recombinant human granulocyte colony-stimulating factor. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for febrile neutropenia.

Febrile Neutropenia Clinical Trials Therapeutic Assessment - Competitive Dynamics

The Febrile Neutropenia drug report insights involve the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Febrile Neutropenia clinical trials:
  • TTY Biopharm
  • Enzychem Lifesciences Corporation
  • Pfizer
  • Gilead Sciences
  • IDION Inc.
  • Sanofi
  • Karius, Inc.
  • Amgen
  • Merck Sharp & Dohme LLC
  • Coherus Biosciences, Inc.
  • S&D Pharma SK s.r.o.
  • Janssen Korea, Ltd.
  • Enzon Pharmaceuticals, Inc.
  • Mylan Inc.
  • Others

Febrile Neutropenia - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for Febrile Neutropenia. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of febrile neutropenia drug candidates.

Pegylated rhG-CSF 100µg/kg

The objective of the study is to assess the safety of pegylated rhG-CSF in preventing neutropenia after chemotherapy in patients with breast cancer. The trial is sponsored by Jiangsu HengRui Medicine Co., Ltd. and is currently under phase II.

Caspofungin Acetate

Merck Sharp & Dohme LLC is developing the drug and is currently under phase II. The study is being conducted to assess the safety of caspofungin acetate as an empirical therapy in pediatric patients having persistent fever and neutropenia.

Reasons To Buy This Report

The Febrile Neutropenia Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for febrile neutropenia. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into febrile neutropenia collaborations, regulatory environments, and potential growth opportunities within febrile neutropenia pipeline insights.

Key Questions Answered in the Febrile Neutropenia - Pipeline Insight Report

  • Which companies/institutions are leading the febrile neutropenia drug development?
  • What is the efficacy and safety profile of febrile neutropenia pipeline drugs?
  • Which company is leading the febrile neutropenia pipeline development activities?
  • What is the current febrile neutropenia commercial assessment?
  • What are the opportunities and challenges present in the febrile neutropenia drug pipeline landscape?
  • What is the efficacy and safety profile of febrile neutropenia pipeline drugs?
  • Which company is conducting major trials for febrile neutropenia drugs?
  • Which companies/institutions are involved in febrile neutropenia collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in febrile neutropenia?

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Febrile Neutropenia
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Types of Febrile Neutropenia
3.5 Diagnosis
3.6 Treatment
4 Patient Profile: Febrile Neutropenia
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Febrile Neutropenia: Epidemiology Snapshot
5.1 Febrile Neutropenia Incidence by Key Markets
5.2 Febrile Neutropenia - Patients Seeking Treatment in Key Markets
6 Febrile Neutropenia: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Febrile Neutropenia: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Febrile Neutropenia, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 Drug Pipeline Comparative Analysis
9.1 List of Febrile Neutropenia Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Febrile Neutropenia Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Drug: Daptomycin
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Drug: ciprofloxacin
10.2.3 Drug: linezolid
10.2.4 Other Drugs
11 Febrile Neutropenia Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Drug: EC-18
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Drug: Filgrastim
11.2.3 Other Drugs
12 Febrile Neutropenia Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Drug: Anidulafungin
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Drug: PledOx (2 µmol/kg)
12.2.3 Other Drugs
13 Febrile Neutropenia Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.3 Other Drugs
14 Febrile Neutropenia, Key Drug Pipeline Companies
14.1 TTY Biopharm
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Enzychem Lifesciences Corporation
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Pfizer Inc.
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Gilead Sciences
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 IDION Inc.
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Sanofi
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 Karius, Inc
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
14.8 Amgen Inc
14.8.1 Company Snapshot
14.8.2 Pipeline Product Portfolio
14.8.3 Financial Analysis
14.8.4 Recent News and Developments
14.9 Merck Sharp & Dohme LLC
14.9.1 Company Snapshot
14.9.2 Pipeline Product Portfolio
14.9.3 Financial Analysis
14.9.4 Recent News and Developments
14.10 Coherus Biosciences, Inc
14.10.1 Company Snapshot
14.10.2 Pipeline Product Portfolio
14.10.3 Financial Analysis
14.10.4 Recent News and Developments
14.11 S&D Pharma SK s.r.o.
14.11.1 Company Snapshot
14.11.2 Pipeline Product Portfolio
14.11.3 Financial Analysis
14.11.4 Recent News and Developments
14.12 Janssen Korea, Ltd.
14.12.1 Company Snapshot
14.12.2 Pipeline Product Portfolio
14.12.3 Financial Analysis
14.12.4 Recent News and Developments
14.13 Enzon Pharmaceuticals, Inc.
14.13.1 Company Snapshot
14.13.2 Pipeline Product Portfolio
14.13.3 Financial Analysis
14.13.4 Recent News and Developments
14.14 Mylan Inc.
14.14.1 Company Snapshot
14.14.2 Pipeline Product Portfolio
14.14.3 Financial Analysis
14.14.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region16 Terminated or Suspended Pipeline Products